Tadalafil Tablet, Film Coated
Product Images NDC 67184-0523

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 67184-0523). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Qilu Pharmaceutical Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Package Label (10mg Bottle Label)

Label for Tadalafil Tablets, USP 10 mg oral film-coated tablets by Qilu Pharmaceutical Co., Ltd. The package contains 30 tablets. The label includes dosage warnings, storage instructions, and a barcode. Manufactured in Haikou, China.*

FDA Label Image

Package Label (10mg Cart)

Tadalafil Tablets, USP 10 mg film-coated tablets packaging label showing a card of 7 tablets. The label includes the active ingredient strength (10 mg), the NDC number 67184-0525-2, and the labeler Qilu Pharmaceutical Co., Ltd. The package states that tablets should not be split and that the entire dose should be taken. The label is primarily white with orange and green text elements.*

FDA Label Image

Package Label (20mg Bottle Label)

Tadalafil Tablets, USP 20 mg film-coated oral tablets label from Qilu Pharmaceutical Co., Ltd. The label states the product strength as 20 mg, indicates the pack contains 30 tablets, and that tablets should not be split. Includes dosage instructions and manufacturer details, along with an NDC and barcode.*

FDA Label Image

Package Label (20mg Cart)

Tadalafil Tablets, USP 20 mg film-coated tablets packaging label. The label indicates a card of 7 tablets, each containing 20 mg of tadalafil. It includes dosing instructions that tablets should not be split and the entire dose should be taken. The labeler is Qilu Pharmaceutical Co., Ltd.*

FDA Label Image

Package Label (2point5mg Bottle Label)

Label for Tadalafil Tablets USP 2.5 mg film-coated oral tablets by Qilu Pharmaceutical Co., Ltd. The package contains 30 tablets with instructions stating once daily use, tablets should not be split, and the entire dose should be taken. The label includes storage instructions, warnings, and an NDC barcode.*

FDA Label Image

Package Label (2point5mg Carton Label)

Packaging label for Tadalafil Tablets, USP 2.5 mg oral film-coated tablets by Qilu Pharmaceutical Co., Ltd. The label specifies a package containing 30 tablets (2 cards of 15 tablets), each with 2.5 mg tadalafil, intended for once daily use. Dosage and storage instructions are visible with a barcode and regulatory information.*

FDA Label Image

Package Label (5mg Bottle Label)

Label for Tadalafil Tablets USP 5 mg, film-coated oral tablets. The package contains 30 tablets and is labeled for prescription use only. The product is manufactured by Qilu Pharmaceutical Co., Ltd. in Jinan, Shandong, China. The label includes dosing warnings to not split tablets and to take the entire dose.*

FDA Label Image

Package Label (5mg Cart)

Packaging label for Tadalafil Tablets, USP, 5 mg film-coated oral tablets from Qilu Pharmaceutical Co., Ltd. The label indicates a bottle containing 30 tablets (2 cards of 15 tablets), with dosage instructions for once daily use. The label also includes the NDC code 67184-0524-2 and a barcode.*

FDA Label Image

Figure (F001)

Four line graphs showing changes in blood pressure measurements (standing systolic, standing diastolic, supine systolic, supine diastolic) over time in hours (0 to 96) comparing tadalafil versus placebo. The y-axis represents the difference in mmHg between tadalafil and placebo treatments, with data points and error bars indicating variability at each time point.*

FDA Label Image

Figure (F002)

Two line graphs depicting changes in systolic blood pressure (BP) over 24 hours post-dose. The top graph shows standing systolic BP, and the bottom graph shows supine systolic BP. Both compare Tadalafil 20 mg with doxazosin 8 mg (solid line) versus placebo with doxazosin 8 mg (dotted line), with BP on the y-axis and time post-dose in hours on the x-axis.*

FDA Label Image

Figure (F003)

A line graph comparing systolic blood pressure (mmHg) over 12 hours following administration of 20 mg tadalafil plus 8 mg doxazosin versus placebo plus 8 mg doxazosin, measured at morning (08:00) and evening (20:00) doses. The graph shows changes in blood pressure over time for each treatment condition.*

FDA Label Image

Figure (F004)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours) for different dosing regimens. It compares single 20-mg and 5-mg tadalafil doses and once-daily 5-mg tadalafil after 5 consecutive days of administration, showing concentration trends and variability over a 120-hour period.*

FDA Label Image

Figure 5 (F005)

A line chart showing change from baseline in IPSS total score over 12 weeks of treatment comparing Tadalafil Tablets 5 mg and placebo. The horizontal axis represents duration of treatment in weeks (0, 4, 8, 12), and the vertical axis shows change from baseline in IPSS score, ranging from 0 to -6. The Tadalafil group line decreases more steeply than the placebo group, with a statistically significant difference indicated at 12 weeks.*

FDA Label Image

Figure 6 (F006)

A line graph showing the change from baseline in IPSS Total Score over 12 weeks of treatment. The graph compares Tadalafil tablets 5 mg versus placebo, with time in weeks on the x-axis and score change on the y-axis. The Tadalafil group shows a greater decrease in score compared to placebo, with statistical significance noted at 12 weeks (p < 0.01).*

FDA Label Image

Figure 7 (F007)

A line graph showing the least-squares mean change from baseline over weeks of therapy (0 to 26 weeks) comparing Tadalafil/Finasteride and Placebo/Finasteride. The graph includes data points at weeks 0, 4, 12, and 26, indicating a greater mean decrease for Tadalafil/Finasteride. Statistical significance markers for p-values below 0.001 and 0.05 are noted.*

FDA Label Image

Figure 8 (F008)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil Tablets 5 mg and placebo. The graph shows Tadalafil 5 mg with a solid line and placebo with a dashed line, illustrating greater score improvement over time for Tadalafil compared to placebo.*

FDA Label Image

Chemical Structure (Structure)

Chemical structure of Tadalafil, depicting its molecular framework with characteristic rings and functional groups as represented in a line-bond diagram format.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.